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(21%) patients. Peri-procedural bradycardia occurred in 99 (24.5%) patients but only 61
(15%) required atropine. Patients with HI had a significantly increased risk of stroke
(OR=2.6, 95% CI 1.2-5.9), myocardial infarction (MI) (OR=4.5, 95% CI 1.2-16.9) or death
(OR=2.7, 95% CI 1.0-7.6) in the peri-operative period. The odds ratio for the combined
endpoint of stroke, MI or death was 3.6 (95% CI 1.8-6.9) in patients with HI.
Conclusions: HI is common after CAS and often requires pharmacological intervention.
Patients with HI are at an increased risk for stroke, MI or death and require close monitor-
ing.
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1116-5 Elevated Preprocedural C-Reactive Protein Levels 
Predict Death and Stroke in Patients After Carotid 
Artery Stenting
David S. Lee, Michael H. Yen, Anjli Maroo, Ravish Sachar, Jakob Schneider, Mary Ellen 
Satava, Samir R. Kapadia, Deepak L. Bhatt, Christopher T. Bajzer, Jay S. Yadav, 
Cleveland Clinic Foundation, Cleveland, OH
Background: Elevated pre-procedural C-reactive protein (CRP) levels are associated
with the composite endpoint of death or myocardial infarction in patients undergoing per-
cutaneous coronary intervention.We sought to determine whether elevated pre-proce-
dural CRP levels predict the composite endpoint of death or stroke in patients who
undergo carotid artery stenting.
Methods: Between December 1999 and August 2002, we examined 133 patients with
pre-procedural CRP levels who underwent carotid artery intervention from a carotid inter-
ventional registry. Using a CRP level of 3.0 mg/L as the cutoff, patients were sub-divided
into high CRP (n=67) and low CRP (n=66) groups. The 30 day and 12 month composite
endpoint of death or stroke were compared between the groups.
Results: No significant differences in baseline demographics were found between the
two groups (including age, gender, coronary artery disease, or prior stroke or transient
ischemic attack), except for hyperlipidemia which was significantly higher in the low CRP
group. For the entire cohort, the death/stroke rates at 30 days and 12 months were 5% (7
events) and 12% (16 events) respectively. The 30 day death/stroke rate was significantly
higher in the high CRP group vs. the low CRP group (10% vs. 0%, p<0.01). This
increased event rate was sustained at one year (19% vs. 5%, p<0.01).
Conclusion: In patients who undergo carotid artery stenting, pre-procedural CRP levels
predict the composite endpoint of death or stroke at 30 days and 12 months.
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1116-6 Long-Term Clopidogrel Therapy Following 
Percutaneous Coronary Intervention Improves Clinical 
Outcome but Is Not Associated With Increased 
Bleeding: New Insights From the CREDO Trial
Herbert D. Aronow, Steven R. Steinhubl, Danielle M. Brennan, Eric J. Topol, Cleveland 
Clinic Foundation, Cleveland, OH, University of Pennsylvania, Philadelphia, PA
Background: In the CREDO trial, the 1-year incidence of major adverse clinical events
(MACE) among patients undergoing or likely to undergo coronary stenting was signifi-
cantly reduced by a pre-procedure clopidogrel loading dose plus 1 year of clopidogrel
compared with no loading dose and 28 days of clopidogrel. Because most patients
undergoing coronary stenting receive 4 weeks of dual antiplatelet therapy with aspirin
and clopidogrel, we sought to determine predictors of bleeding and occurrence of major
events between day 29 and 1 year among patients enrolled in the CREDO trial.
Methods: Patients who survived to day 29 were included (n=2068) in this intent-to-treat
analysis. Minor and major bleeding events (TIMI criteria) were pooled into a composite of
any bleeding. MACE was a composite of death, non-fatal myocardial infarction (MI) and
stroke.
Results: From day 29 through 1 year there were 138 bleeding events, 68 in the clopi-
dogrel and 70 in the placebo arm (p=0.84). Of these, 112 (81%) were procedure-related,
and most (82, 59%) occurred in the setting of coronary artery bypass graft surgery
(CABG). In a multivariable model including demographics, comorbidities and concomi-
tant medical therapies, the only significant independent predictors of bleeding were
increasing age, diabetes (DM), and CABG (model chi square 398, p < 0.001, c statistic
0.85); clopidogrel therapy beyond 28 days was not a significant predictor of major or
minor bleeding. During that same interval, 80 MACE occurred. First MACE was signifi-
cantly less frequent among those randomized to clopidogrel than placebo (3.0 vs. 4.7%,
p=0.043).
Conclusions: With the sustained use of dual antiplatelet therapy from 1 month to one
year after percutaneous coronary intervention, there is a significant 36% reduction of
death, MI, and stroke without any increase in bleeding events.
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1116-7 Similar Outcomes Between Patients With Native 
Coronary and Bypass Graft Disease Treated With 
Sirolimus-Eluting Stents in the SECURE Trial
Costa Marco, Teirstein Paul, MB Leon, Theodore Bass, Tim Fischell, Andrew Carter, 
Yakubov Steven, University of Florida Jacksonville, Jacksonville, FL, FL
Background: Bare metal stenting or CABG has provided limited success for the treatment
of bypass graft disease. The efficacy of Sirolimus-eluting Bx Velocity stents (SES) in
native coronary arteries is proven, however its application in bypass grafts remains
unknown. We compared the long-term results between patients with native coronary dis-
ease versus those with graft disease treated with sirolimus-eluting stents as part of
SECURE trial.
Methods and Results: Patients (n=252) with a serious disease or condition for which
there was no acceptable alternative treatment available were enrolled. Out of 202
patients with complete 6-month follow-up, 58 patients had 75 graft lesions (GI) and 144
patients had 286 lesions in native vessels (GII). There were more males in GI(83%) ver-
sus GII (67%). Other baseline characteristics were similar, with 39% diabetics in each
group. 71% of lesions in GI and 58% of lesion in GII were treated with previous brachy-
therapy. All patients received aspirin and clopidogrel for at least 6 months. Angiographic
vessel diameter, determined by the core lab, was larger in GI (2.26mm) versus GII
(1.92mm). Likewise, in-stent MLD post procedure was 2.52mm (GI) and 2.18mm (GII).
Mean total stent length was 23.3mm in both groups. There was no in-hospital adverse
event in GI and 1 death (0.7%) in GII. After 6 months, 13.8% of patients in GI versus
10.4% of patients in GII had at least one major adverse event (death, myocardial infarc-
tion, target lesion revascularization or emergent CABG). TVR rate was 12.1% in GI and
9% in GII. Updated data with angiographic follow-up will be available for presentation.
Conclusion: In the SECURE trial, which enrolled a very high risk group of patients, the
use of sirolimus-eluting stent to treat bypass graft disease was feasible, safe and pro-
vided acceptable long-term results compared to the outcomes of patients with native cor-
onary disease.
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1116-8 Early and Mid-Term Results of Cypher Stents in 
Unprotected Left Main
Alaide Chieffo, Dejan Orlic, Flavio Airoldi, Iassen Michev, Matteo Montorfano, Nicola 
Corvaja, Ghada W Mikhail, Davide Maccagni, Antonio Colombo, San Raffaele Hospital, 
Milan, Italy, EMO Centro Cuore Columbus, Milan, Italy
The safety and efficacy of percutaneous coronary intervention in unprotected left main
(ULM) coronary arteries confronts with the problems associated with restenosis.
Methods From April 2002 32 consecutive patients were electively treated in our instution
with the implantation of Cypher (Cordis, Johnson and Johnson Company, Warren,
NJ)Sirolimus-eluting stent (SES) in unprotected left main.
Results 4 patients (12.5%) were diabetics, 7 (22%) had unstable angina, mean age was
58±13 years, and EF was 51± 6.6 %. The site of the lesion in LM was ostial in 3 (9.3%)
patient, mid-portion of the artery in 3 patients (9.3%) and distal in 27 ( 84.3%) patients
(bifurcation in 21pts and trifurcation in 6). In 19 (70%) patients with distal LM disease
both branches were stented with SES, kissing balloon inflation was performed in 15
(55.5%). Only POBA in side branch was performed in 3 patients (11%), 5 pts had no
treatment in the side branch. The largest nominal diameter of SES available was 3.0 mm
(6 cells). Angiographic as well as procedural success was achieved in all patients. Elec-
tive intra-aortic balloon pump was used in 4 patients and GP IIb/IIIa antagonists were
used in 16 (50 %) patients. During hospitalization, no patient died, nor had myocardial
infarction (MI) or CABG , one patient had repeated PTCA due to residual dissection distal
to the Cypher stent. At 6 month clinical follow-up 1 patient died after discontinuing antiag-
gregant theraphy because of acute pancreatisis, 6 (18.7%) patients had TLR (4 re-PCI
and 2 CABG) and 1 had MI. Angiographic follow-up was achieved in 23 pts (74%). Rest-
enosis occurred in 6 patients; all restenostic lesions were located in the distal LM.
Conclusions In this early experience with Cypher stents in ULM we can state that the
problem of in-stent restenosis is still present mainly at the level of the bifurcation. We can
speculate that the usage of 3 mm stents (6 cells) in vessels usually larger than 3.5mm
could have contributed to inhomogeneous drug delivery to the vessel wall.
Noon
1116-9 Trends in Fibrinolytic Therapy and Intra-Aortic Balloon 
Pump Counterpulsation Utilization in Patients With 
Cardiogenic Shock Complicating Acute Myocardial 
Infarction in Hospitals Without Percutaneous 
Transluminal Coronary Angioplasty/Coronary Artery 
Bypass Graft Capability: Observations From the 
National Registry of Myocardial Infarction
Anvar A. Babaev, Paul D. Frederick, Delia Cotiga, Judith S. Hochman, NYU Medical 
Center, New York, NY, Ovation Research Group, Seattle, WA
Background: Treatment of patients (pts) in cardiogenic shock (CS) complicating acute
myocardial infarction (AMI) with fibrinolytic therapy (FT) and intra-aortic balloon pump
counterpulsation (IABP) in hospitals without PTCA/CABG capability is associated with
mortality reduction.
Objectives: We determined trends in utilization of FT, IABP, and mortality rates for
patients in CS complicating AMI in the National Registry of Myocardial Infarction (NRMI)
population for hospitals without PTCA/CABG capability.
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Methods: From 07/94 to 10/01 the NRMI accrued 3,768 pts with AMI complicated by CS
from 980 hospitals without PTCA/CABG capability. Trends in baseline characteristics, in-
hospital mortality, transfer rates to hospitals with PTCA/CABG capability, and manage-
ment patterns were evaluated.
Results: The mean age of the group was 71.3 + 12.5 years. There were no differences
over time in age, % women, stroke, and prior CABG. There were fewer pts in recent
years with history of MI (p<0.001), but more pts with prior PTCA, CHF, HTN and dyslipi-
demia (p<0.05). There was a trend of reduction in use of FT from 39.5% to 31.4%
(p=0.05), and very low rates of IABP use that did not change over time (5.7% to 5.3%, p=
N.S.). Mortality was very high and unchanged over time (84.5% to 85.2%, p=N.S.). Over-
all transfer-out rates increased (p<0.0001) from 27.7% to 33.9%. However, transfer-out
rates remained relatively flat over last 4 years (32.7%, 33.3%, 34.8%, 33.9%, respec-
tively), with mortality rates increasing over that time period (81.2%, 83.9%, 85.3%,
85.9%, respectively), but FT rates continued to decrease (36.2%, 38.2%, 36%, 31.4%,
respectively).
Conclusion: FT and IABP were underutilized in hospitals without PTCA/CABG capabil-
ity. Mortality was very high and unchanged over time. Furthermore, FT utilization was
decreasing despite the fact that transfer out rates remained unchanged over the last sev-
eral years. Overall, most registered pts did not receive FT or IABP, and were not trans-
ferred out to hospitals with PTCA/CABG capability. For hospitals without PTCA/CABG
capability we recommend an early FT and IABP, followed by immediate transfer to
regional centers for revascularization for patients < 75 years of age.
Noon
1116-10 Shock in Patients With Acute Aortic Dissection: Clinical 
Characteristics, Risk Factors, and Outcomes
Thomas T. Tsai, Eric M. Isselbacher, Christoph A. Nienaber, Arturo Evangelista, 
Jianming Fang, Dean E. Smith, Jeanna V. Cooper, Stuart Hutchison, Eduardo Bossone, 
Patrick O'Gara, Kim A. Eagle, Rajendra H. Mehta, On behalf of the International Registry 
of Acute Aortic dissection, University of Michigan, Ann Arbor, MI
Background: Shock often complicates acute aortic dissection (AAD). However, the clini-
cal characteristics, risk factors and outcomes of shock in patients with AAD are not
known. Methods: Accordingly, we studied 1073 AAD patients enrolled in the Interna-
tional Registry of Acute Aortic Dissection (IRAD) between 1996 and 2001. Results:
Shock occurred in 313 (29.2%) AAD patients (46.0% on admission and in the remaining
after admission) and was more common in patients with acute type A than type B dissec-
tion (37.9% vs. 14.6%, p<0.0001). The proportion of patients with shock increased with
advancing age (p for trend =0.043). Multivariate logistic regression identified age >70
years (OR, 2.0; 95% CI, 1.4-2.9; P<0.0001), type A dissection (referent type B AAD, OR
2.1, 95% CI, 1.4-3.2, p=0.0002), neurologic deficit (OR 3.8; 95% CI, 2.2-6.6; P<0.0001),
syncope (OR 2.9; 95% CI, 1.8-4.7; P<0.0001), aortic regurgitation requiring valve sur-
gery (OR 1.9, 95% CI 1.1-3.3, P=0.024), cardiac tamponade (OR 5.1, 95% CI 3.0-8.8,
P<0.001) and new Q wave or ST segment deviation on ECG (OR 1.6; 95% CI, 1.1-2.4;
P=0.014) as independent associations of shock (c-statistic 0.78, Hosmer Lemeshow χ2
5.78, degrees of freedom 8, p=0.67). To validate our model and examine its ability to dis-
criminate, we used the bootstrap resampling technique, and calculated the ROC curves
of 1000, 100% samples of data with replacement. The area under the average curve was
0.79 (95% CI 0.75 to 0.82), indicating a good ability of the model to discriminate between
patients with AAD who had shock and those who did not. Hospital complications (neuro-
logical deficits [22.7% versus 12.0%], altered mental status [26.1% versus 4.4%], myo-
cardial [14.6% versus 6.9%], mesenteric [6.9% versus 2.6%] or limb ischemia [14.6%
versus 6.9%]); and death [55.0% versus 10.3%] occurred more frequently in patients with
shock than in those without it (P<0.001 for all comparisons). Conclusions: Shock
occurred in more than a quarter of AAD patients and was associated with a much higher
in-hospital adverse event rate. Our study identified factors associated with shock in AAD
patients. Knowledge of these associations may be useful to clinicians as they triage and
treat patients with AAD.
Noon
1116-11 The Mineralocorticoid Paradox: Profibrotic In Vivo in 
Experimental Asymptomatic Left Ventricular 
Dysfunction but Antifibrotic In Vitro
Lisa C. Costello-Boerrigter, Guido Boerrigter, Gail J. Harty, Alessandro Cataliotti, Denise 
M. Heublein, Sharon M. Sandberg, John A. Schirger, Fernando L. Martin, Margaret M. 
Redfield, John C. Burnett, Jr., Mayo Clinic and Foundation, Rochester, MN
Background: Asymptomatic left ventricular dysfunction (ALVD) has maintenance of
sodium (Na) excretion and activation of natriuretic peptides (NP), but not aldosterone
(ALDO). Normal subjects escape the Na and water retaining effects of exogenous deoxy-
corticosterone acetate (DOCA), an ALDO precursor. Overt congestive heart failure
(CHF) cannot escape ALDO or DOCA's actions, resulting in worse edema. ALDO may
cause cardiac hypertrophy and fibrosis. In clinical trials ALDO antagonism benefited CHF
patients perhaps due to antifibrotic effects. ALVD’s response to DOCA excess is
unknown. We hypothesized that: (1) in ALVD exogenous DOCA would result in Na and
fluid retention, (2) DOCA excess in ALVD would give cardiac fibrosis, and (3) collagen
synthesis would increase in cardiac fibroblasts (CF) incubated with ALDO.
Methods: Cardiorenal function was assessed in two groups of ALVD dogs induced by
180 bpm tachypacing. One group was a control (A); the other (A+D) received DOCA (1
mg/kg/d i.m.) starting pacing day 2. Collagen area fraction was measured in picrosirius
red stained left ventricle. The effect of ALDO (10-9 M, 10-6 M) on DNA and collagen syn-
theses in canine CF from normal left ventricle was determined by [3H]-thymidine and
[3H]-proline incorporation.
Results: Urinary flow (UVolR) and Na excretion (UNaV) were unchanged in A, with no
ALDO activation. In contrast, in A+D UNaV decreased the first two days DOCA was
given, but normalized on day 4 despite continuing DOCA. Increased UVolR and urinary
cGMP excretion occurred with DOCA escape. No differences in cardiorenal parameters
existed on day 11. Collagen area fraction in A+D was significantly higher than in A,
3.6±0.4% vs 2.0±0.2% (p=0.02). Conversely, ALDO (10-6M) added to CF decreased
[3H]-proline and [3H]-thymidine incorporation (both p<0.01).
Conclusion: ALVD escapes DOCA’s Na retaining effects. Despite A+D’s renal escape,
this group had more cardiac fibrosis than A. Hence, the heart did not escape DOCA’s tis-
sue effects. However, ALDO failed as a direct stimulator of collagen synthesis in CF. This
paradox of mineralocorticoid induced fibrosis in vivo but not in vitro suggests that ALDO’s
profibrotic effects require another factor’s presence.
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1116-12 PG-530742, a Novel Matrix Metalloproteinase Inhibitor, 
Improves Left Ventricular Function and Attenuates 
Remodeling in Dogs With Chronic Heart Failure
Hani N. Sabbah, Hideaki Morita, George Suzuki, Victor G. Sharov, Anastassia Todor, 
Timothy P. O'Neill, Henry Ford Health System, Detroit, MI, Procter and Gamble 
Pharmaceuticals, Mason, OH
Background: PG-530742 (PG) is a hydroxamic-based matrix metalloproteinase (MMP)
inhibitor that is 2 to 3 orders of magnitude more potent as an inhibitor of MMP-2, -3, -8, -
9, -13 and -14 than MMP-1 and -7. This study examined the effects of chronic monother-
apy with PG on LV function and remodeling in dogs with coronary microembolization-
induced heart failure (HF). Methods: A blinded, randomized, placebo-controlled design
was used. Dogs were randomized to 3 months therapy with low dose (LD) PG (0.2 mg/
kg, tid, n=8), high dose (HD) PG (3.5 mg/kg, tid, n=8) or placebo (PL) (vehicle, tid, n=8).
LV ejection fraction (EF), end-diastolic (EDV) and end-systolic volumes were measured
from ventriculograms at time of randomization (PRE) and after 3 months of therapy
(POST). At POST, hearts were removed and LV tissue used to measure cardiomyocyte
cross-sectional area (MCSA), a measure of myocyte hypertrophy and volume fraction of
interstitial fibrosis (VFIF). Results: In PL-treated dogs, EDV and ESV increased and EF
decreased (Table). LD-PG elicited changes similar to PL. In contrast, HD-PG decreased
EDV and ESV and increased EF. MCSA was not different with LD-PG compared to PL
(737 ± 28 vs 688 ± 26 um2) but decreased with HD-PG (498 ± 22 um2, P<0.05). VFIF
was not different with LD-PG compared to PL (15 ± 1 vs 14 ± 1 %) but decreased with
HD-PG (10 ± 1 %, P<0.05). Conclusions: In dogs with HF, chronic therapy with HD-PG
improves LV function and attenuates LV remodeling. PG may be useful as adjunct ther-
apy for treatment of chronic HF.
Noon
1116-13 Chronic Therapy With Eplerenone Reduces Tubulin-
Alpha and -Beta mRNA Expression and Increases Titin 
mRNA Expression in Dogs With Heart Failure
Sharad Rastogi, Sudhish Mishra, Ramesh Gupta, George Suzuki, Hideaki Morita, Sidney 
Goldstein, Hani N. Sabbah, Henry Ford Health System, Detroit, MI
Background: Titin, a cytoskeletal protein that ensures elasticity and extensibility of the
sarcomere is decreased in heart failure (HF) leading to increased LV stiffness. Tubulin
(TU), a cytoskeletal protein consisting of an alpha and a beta isoforms increases in HF
and can lead to contractile dysfunction and loss of compliance. We previously showed
that eplerenone (EPL), a new aldosterone receptor blocker, reduces LV end-diastolic wall
stress, stiffness and improves relaxation in dogs with HF. This study examined the effects
of EPL on titin and TU-alpha and -beta mRNA expression in LV tissue of dogs with coro-
nary microembolization-induced HF. Methods: Dogs were randomized to 3 months ther-
apy with EPL (10 mg/kg Bid, n=7) or to no therapy (control, n=7). Tissue from 6 normal
(NL) dogs was used for comparison. LV tissue from all dogs was used to extract RNA.
mRNA expression for titin and TU was measured using reverse transcriptase polymerase
chain reaction and bands quantified in densitometeric units. Results: Data shown in
table. Compared to NL, titin mRNA expression decreased in controls and returned to
near NL with EPL. mRNA expression for TU-alpha and -beta increased in controls com-
pared to NL and returned to near NL with EPL. Conclusions: In dogs with HF, mRNA
expression for titin is decreased and mRNA expression for TU-alpha and -beta is
increased. EPL therapy normalized expression of both genes. This restoration of key
cytoskeletal proteins partly explains the improvement in LV diastolic function seen with
EPL.
Placebo LD-PG-530742 HD-PG-530742
PRE POST PRE POST PRE POST
EDV (ml) 57 + 2 63 + 2* 58 + 2 63 + 2* 59 + 4 57 + 4*
ESV (ml) 36 + 1 42 + 2* 38 + 2 43 + 2* 38 + 2 34 + 2*
EF (%) 36 + 1 33 + 1* 35 + 1 31 + 1* 36 + 1 40 + 1*
*=p<0.02 PRE vs. POST
